Correlation Analysis Between Peripheral Blood PrPC Levels and Disease Severity and Prognosis in Patients With Acute Cerebral Infarction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07513428

Enrollment

Registered

2026-04-07

Start date

2023-06-06

Completion date

2024-09-01

Last updated

2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Cerebral Infarction

Keywords

acute cerebral infarction, the cellular prion protein, CD4+T cells

Brief summary

The primary objective of this observational study is to investigate alterations in PrPc levels in peripheral blood during acute cerebral infarction, as well as the correlation between these changes and both disease severity and prognosis. Additionally, it aims to explore the association between peripheral blood PrPc and T-cell-mediated inflammatory responses in acute cerebral infarction. Key research questions addressed include: how PrPc concentrations in peripheral blood change during acute cerebral infarction, and whether such variations correlate with clinical severity and patient outcomes. No interventions were administered in this study, and all patients received standard diagnostic and therapeutic care without disruption. Fasting venous blood samples were collected on the morning following hospital admission, and follow-up assessments using the modified Rankin Scale (mRS) were conducted at 90 days post-onset.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with anterior circulation ischemic stroke who were admitted to the Department of Neurology of the First Hospital of Jilin University within 48 hours of symptom onset and were aged 18-80 years

Exclusion criteria

* (1) patients who received intravenous thrombolysis or endovascular intervention; (2) patients with infectious diseases, autoimmune diseases, or those receiving immunosuppressive or immunomodulatory therapy; (3) patients with a history of cerebral infarction or intracerebral hemorrhage within the past year; (4) patients with severe hepatic or renal dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding three times the upper limit of normal, serum creatinine levels \>265 μmol/L, heart failure, or malignant tumors.

Design outcomes

Primary

Measure	Time frame	Description
3-month mRS	three months after the onset of the disease	Functional outcomes were assessed at 3 months by trained medical personnel via telephone interviews using the modified Rankin Scale (mRS). Favorable outcomes were defined as no symptoms to mild disability (mRS 0-2), whereas unfavorable outcomes were defined as moderate disability to death (mRS 3-6).

Countries

China

Outcome results